Skip to main content

Table 1 Serum IgG antibodies directed to AQP4 and MOG (high-titer MOG-IgG antibodies at ≥ 1:160) in patients with CNS demyelinating diseases

From: Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders

Disease

Number

Females1

Age (y)2

AQP4-IgG1,3

MOG-IgG1,3

NMO

45

41 (91%) *

50 (2-80)

43 (96%) §

3 (7%)

    

1,280

2,560

    

(40-40,960)

(160-2,560)

HR-NMO

53

34 (64%)

48 (13-74)

32 (60%) §

7 (13%)

    

1,280

2,560

    

(20-20,480)

(640-5,120)

ADEM

33

20 (61%)

12 (2-52) §

0 (0%)

14 (42%) §

    

-

2,560

     

(160-20,480)

CIS

32

22 (69%)

34 (5-57) +

1 (3%)

2 (6%)

    

640

(640; 5,120)

MS

71

43 (61%)

40 (14-66)

0 (0%)

2 (3%)

     

(160; 160)

CTRL

101

79 (78%)

43 (14-84)

0 (0%)

3 (3%)

     

320

     

(160-640)

p-value

 

0.003

< 0.001

< 0.001

< 0.001

  1. P-value: groups were compared using1 Chi-Square test with Fisher's exact post-hoc test and2 Kruskal-Wallis test with Dunn's post-hoc test (data are shown as median with range);3 median titer level (range) of MOG-IgG or AQP4-IgG seropositive samples; * statistically different from HR-NMO, ADEM and MS; + statistically significant from NMO, HR-NMO and ADEM; § statistically significant from all other groups (p-values were corrected for multiple comparisons). Abbreviations: y = years, NMO = Neuromyelitis optica, HR-NMO = High-risk NMO, ADEM = acute disseminated encephalomyelitis, CIS = clinically isolated syndrome, MS = multiple sclerosis, CTRL = controls.